Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Neurobiol Aging. 2020 Apr 8;92:61–72. doi: 10.1016/j.neurobiolaging.2020.03.020

Table 3:

Subgroup analyses - Adjusted* mean cognitive assessment composite z-scores by intervention assignment, and baseline menopausal status.

Mean (SE) Relative Intervention Effects: ILI minus DSE Mean (95% CI) Difference in Intervention Effects Between Pre/<5 yrs. vs >10 yrs.***
Pre- or <5 years Post-menopausal 5–10 years Postmenopausal >10 years Postmenopausal p-value**
APOE4
Non APOE4 carrier 0.15 (0.07) −0.11 (0.09) −0.14 (0.05) 0.0040 0.29 (0.11, −0.46)
APOE4 carrier −0.09 (0.12) −0.14 (0.16) 0.05 (0.10) 0.5388 −0.13 (−0.45, −0.18)
P = 0.0648
HRT
Yes 0.13 (0.09) −0.10 (0.08) −0.05 (0.05) 0.1177 0.18 (−0.01, −0.38)
No 0.08 (0.07) 0.04 (0.11) −0.05 (0.08) 0.4775 0.13 (−0.08, −0.34)
P = 0.6302
BMI
25–29 0.23 (0.16) 0.08 (0.19) 0.10 (0.10) 0.7610 0.13 (−0.24, −0.50)
30–39 0.11 (0.07) −0.09 (0.08) −0.09 (0.05) 0.0667 0.20 (0.02, −0.38)
40+ 0.04 (0.09) 0.10 (0.13) −0.08 (0.09) 0.4614 0.12 (−0.14, −0.38)
P = 0.6710
*

In addition to intervention and baseline menopausal status, models are adjusted for whether or not cognitive function had been assessed previously and the following baseline factors: education, race/ethnicity, CVD history, hypertension status, and HbA1c%.

**

Test for two-way interaction;

***

Test for three-way interaction and 95% confidence intervals